Search Results

You are looking at 1 - 10 of 815 items for :

  • Refine by Access: All x
Clear All
Full access

Shira Dinner and Ranjana Advani

/print certificate. Release date: August 22, 2013; Expiration date: August 22, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Describe the rationale for targeted therapy in patients with relapsed classical HL

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

ultimately experience relapse and require further therapy. Prognosis associated with relapsed MM is generally poor, with a median overall survival of less than 1 year among patients who have received 2 or more prior lines of therapy. 20 Definition of

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

brain, and less frequently to bone. 2 , 3 Understanding the determinants of distant relapse is critical because survival for patients with TNBC after metastatic diagnosis ranges from 17 3 , 4 to 25 months. 5 Most metastatic recurrences of TNBC occur

Full access

Presented by: Matthew J. Matasar

With only approximately half of patients eligible to receive curative autologous stem cell transplant (ASCT), outcomes remain poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). At the NCCN 2021 Virtual

Full access

Jorge J. Castillo

Numerous advances have recently been made in the treatment of relapsed/refractory (R/R) multiple myeloma (MM): novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have

Full access

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz

performance status, multiple comorbidities, inability to tolerate chemotherapy, and multidrug resistance. 2 The management of patients with relapsed/refractory AML remains a huge clinical challenge with few therapeutic options available, particularly for

Full access

Presented by: Mazyar Shadman

Despite advancements in treatment, mantle cell lymphoma (MCL) is still considered incurable, and most patients experience relapsed/refractory (R/R) disease. However, according to Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research

Full access

Kenneth C. Anderson

gains expected from maintenance therapy. “But new approaches are still needed to treat and ultimately prevent relapse. Fortunately, there are exciting novel targeted agents on the horizon,” he said. First-Line Combinations After the second

Full access

Nina D. Wagner-Johnston and Nancy L. Bartlett

patients with relapsed lymphoma can be cured with autologous stem cell transplant, led to the adoption of CT for monitoring patients for early relapse. The frequency with which CT was used in the posttreatment setting largely mimicked the interval adopted

Full access

Aliza Gardenswartz and Mitchell S. Cairo

Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin’s lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. 1 – 3 However, those with relapsed and/or refractory (R